recovered billions of dollars on behalf of investors.
A securities class action has been filed in the USDC – S.D.CA. against aTyr Pharm, Inc. (ATYR) (“aTyr” or the “Company”), on behalf of all persons and entities that purchased or otherwise acquired aTyr common stock, purchased call options on aTyr common stock, and/or sold put options on aTyr common stock between January 16, 2025, and September 12, 2025, both dates inclusive (the “Class Period”).
aTyr describes itself as a clinical-stage biotechnology company leveraging evolutionary intelligence to develop novel therapies targeting fibrosis and inflammation. The Company focuses on the biology of tRNA synthetases—so called ancient and essential proteins that, beyond their traditional roles, have evolved unique extracellular domains that influence diverse signaling pathways in humans. Through its proprietary discovery platform, aTyr explores these domains across all 20 tRNA synthetases to uncover previously hidden therapeutic targets. The Company’s lead candidate, Efzofitimod, is a biologic immunomodulator in clinical development for treating interstitial lung disease, pulmonary sarcoidosis in particular.
The complaint alleges defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug’s capability to allow a patient to completely taper their steroid usage. This caused Plaintiff and other shareholders to purchase aTyr’s securities at artificially inflated prices.
As a result, investors and analysts reacted immediately to aTyr’s revelation. The price of aTyr’s common stock declined from a closing market price of $6.03 per share on September 12, 2025 to $1.02 per share on September 15, 2025, a decline of 83.2% in the span of just a single day.
If you purchased aTyr common stock, purchased call options on aTyr common stock, and/or sold put options on aTyr common stock during the Class Period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.